IP Library Granted Patent US 10,682,404
Granted Patent B2
US 10,682,404 · App. 16/582,413 · Granted Jun 16, 2020

Targets of

Inventors: Simon Urwyler (Bern, CH); Markus Haake (Bern, CH); Michael Rudolf (Ittigen, CH)
A61K39/1045A61K39/104C07K14/212C07K14/22C07K16/1217A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,682,404
App. No.
16/582,413
Granted
Jun 16, 2020
Kind
B2
Abstract

The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Claims (18)

1. An immunogenic composition comprising:

an isolated polypeptide encoded by a recombinant nucleic acid molecule consisting of the polynucleotide sequence of SEQ ID NO: 13; and,

an immuno-effective amount of an adjuvant;

wherein the composition is effective in generating an immune response against Acinetobacter baumannii in a subject in need thereof.

2. The immunogenic composition of claim 1 , wherein the polypeptide is isolated by a process comprising:

(i) providing a host cell transformed/transfected with an expression vector comprising said recombinant nucleic acid sequence of SEQ ID NO 13,

(ii) growing the cell, and

(iii) purifying the polypeptide from the cell or the cell's growth environment.

3. The immunogenic composition of claim 1 , wherein the polypeptide further comprises a His tag.

4. The immunogenic composition according to claim 1 , further comprising an effectively immunogenic delivery vehicle.

5. The immunogenic composition of claim 1 , wherein the composition does not comprise any additional Acinetobacter baumannii polypeptides.

6. The immunogenic composition of claim 1 , wherein the adjuvant is selected from the group consisting of virosomes, Freund's adjuvants (complete and incomplete), Gerbu adjuvant, mycobacteria, cholera toxin, tetanus toxoid, E. coli heat-labile toxin, quil-saponin mixtures, MF59, MALP-2, ISCOMs, aluminum hydroxide, aluminum phosphate, calcium phosphate, lysolecithin, pluronic polyols, polyanions, peptides, keyhole limpet hemocyanins, dinitrophenol, saponins, muramyl dipeptides, CpG dinucleotides, CpG oligonucleotides, monophosphoryl lipid A, polyphosphazenes, virus-like particles, and cochleates.

7. An immunogenic composition comprising:

an isolated recombinant antigenic polypeptide consisting of the amino acid sequence SEQ ID NO: 14 having immunostimulatory activity in combination with an immuno-effective amount of an adjuvant.

8. The immunogenic composition of claim 7 , further comprising:

one or more polypeptides selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, and 16.

9. The immunogenic composition of claim 7 , wherein the composition does not comprise any additional Acinetobacter baumannii polypeptides.

10. The immunogenic composition of claim 7 , wherein the adjuvant is selected from the group consisting of virosomes, Freund's adjuvants (complete and incomplete), Gerbu adjuvant, mycobacteria, cholera toxin, tetanus toxoid, E. coli heat-labile toxin, quil-saponin mixtures, MF59, MALP-2, ISCOMs, aluminum hydroxide, aluminum phosphate, calcium phosphate, lysolecithin, pluronic polyols, polyanions, peptides, keyhole limpet hemocyanins, dinitrophenol, saponins, muramyl dipeptides, CpG dinucleotides, CpG oligonucleotides, monophosphoryl lipid A, polyphosphazenes, virus-like particles, and cochleates.

Assignments (2)
SECURITY INTEREST Recorded Jun 21, 2023
From: ARIDIS PHARMACEUTICALS, INC.; ARIDIS BIOPHARMACEUTICALS, LLC; ARIDIS PHARMACEUTICALS, C.V.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 064020/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2023
From: URWYLER, SIMON; HAAKE, MARKUS; RUDOLF, DR. MICHAEL
To: ARIDIS PHARMACEUTICALS, INC.
Reel/Frame 063192/0498 →
Priority Claims (1)
EP 11191320 · Nov 30, 2011 · regional
Continuity (4)
Continuation 15897480 · Feb 15, 2018
Division 15427976 · Feb 8, 2017
Division 14362058
Related Publication 20200016258A1 · Jan 16, 2020